Private equity (PE) participation in US healthcare has accelerated over the past decade, drawing scrutiny from federal and state regulators as well as politicians. While the Biden-era FTC and DOJ framed PE-backed ‘roll-ups’ as threats to competition and patient welfare, early actions under the second Trump administration signalled a return to a less-hostile view of private equity. In recent years, at least 15 states passed ‘mini-HSR’ statutes to facilitate review of smaller deals, particularly in healthcare. Recent headline cases – US Anesthesia Partners/Welsh Carson, JAB-Ethos Veterinary and Surmodics/GTCR – illustrate the agencies’ willingness to challenge acquisitions involving private equity firms and attempts to craft forward-looking relief that may affect future deal making.
Read the full article: Why US Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector //
Source: https://globalcompetitionreview.com/review/the-antitrust-review-of-the-americas/2026/article/why-us-regulators-are-cracking-down-private-equity-investments-in-the-healthcare-sector
